BeiGene, Ltd. (SHA:688235)

Market Cap	211.88B
Revenue (ttm)	27.81B
Net Income (ttm)	-4.71B
Shares Out	n/a
EPS (ttm)	-44.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,011,012
Average Volume	2,518,197
Open	245.50
Previous Close	249.51
Day's Range	244.66 - 254.00
52-Week Range	111.22 - 254.00
Beta	0.65
RSI	71.34
Earnings Date	May 14, 2025

About BeiGene

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a mo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688235

Financial Performance

In 2024, BeiGene's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Financial numbers in USD